Table 3.

Comparison of toxicity and side effects in different GEJ carcinoma trials

Clinical Trial	ACCORD07	CROSS	Stahl 2009
Number of patients randomized	224	368	126
Patients with at least grade 3 toxicity	38%	Hematologic: 7.6% All other: 13%	Unspecified
Grade 3 – and 4 toxicity in control arm	-	-	5% (CT arm as control arm)
Grade 3–4 leukopenia during CT/CRT	5.5%	6%	12%
Grade 3–4 neutropenia during CT/CRT	20.2%	2%	unspecified
Grade 3–4 thrombocytopenia during CT/CRT	5.5%	1%	5%
Progressive disease during preoperative therapy	11%	Absolute number unspecified; 7 patients (4%) did not undergo surgery because of disease progression	10%
Deaths during CT/CRT	1%	1%	One patient (2%) died in CT group; none died in CRT group

Side effects and toxicity in GEJ carcinoma trials; in CROSS- and ACCORD07 trial, surgery only was defined as control arm; in Stahl 2009, CT arm was considered as control arm, CRT was considered as CT/CRT arm.